Hinova registers Phase 3 trial of Deutenzalutamide in high-risk BCR prostate cancer
Hinova Pharmaceuticals Inc. has registered a Phase 3, randomized, double-blind, placebo-controlled study of Deutenzalutamide plus androgen deprivation therapy versus placebo plus ADT in patients with high-risk biochemical recurrence of prostate cancer. The study plans to enroll 1044 participants and is expected to start on October 31, 2026, with primary completion projected for December 31, 2029.
Primary source
ClinicalTrials.gov registry record, October 15, 2026
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
Read the source: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation